Wisconsin Medicaid spending on GLP-1 drugs

How much did Wisconsin Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $327.8 million for GLP-1 drugs paid through Wisconsin Medicaid in 2025, across at least 302,672 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 18 rows of 168, so these figures are floors.

Pharmacies were reimbursed at least $99.7 million for GLP-1 drugs paid through Wisconsin Medicaid in 2026 (quarter 1 only, as posted so far), across at least 91,305 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 4 rows of 45, so these figures are floors.

By year and ingredient

2020at least $92,792No data$12,268,279at least $22,425,398at least $4,477,223SuppressedNo dataat least $39,263,692
2021at least $834,851No data$17,411,429at least $51,536,881at least $1,453,444SuppressedNo dataat least $71,236,605
2022at least $5,387,783at least $10,413$25,543,383at least $79,593,292at least $635,376SuppressedNo dataat least $111,170,247
2023at least $24,698,760at least $672,943$27,681,954at least $100,162,975at least $339,578SuppressedNo dataat least $153,556,210
2024at least $77,661,719$50,176,705at least $8,319,256at least $74,454,017at least $310,534No dataSuppressedat least $210,922,231
2025at least $108,457,539at least $126,242,979at least $3,924,681at least $89,105,648at least $85,740No dataat least $31,257at least $327,847,844
2026 (Q1)at least $37,422,746$45,130,663at least $597,621at least $16,524,298$12,279No data$14,102at least $99,701,709

By product, 2025

Ozempicat least $21,799,759at least 22,0452 of 14
Rybelsus$311,7543090 of 12
Wegovy$86,346,02765,1140 of 20
Mounjaro$7,925,5607,4320 of 24
Zepboundat least $118,317,420at least 110,6881 of 25
Liraglutide (generic name listing)at least $1,624,812at least 3,2672 of 26
Saxenda$1,558,0171,3740 of 4
Victoza$741,8521,1790 of 8
Trulicityat least $89,105,648at least 91,1226 of 22
BydureonSuppressedSuppressed2 of 2
Byettaat least $64,317at least 762 of 4
Exenatide (generic name listing)at least $21,422at least 271 of 3
Soliquaat least $31,257at least 392 of 4

By quarter, 2025

Q1 2025at least $72,599,290at least 67,1562 of 38
Q2 2025at least $79,802,148at least 73,5368 of 43
Q3 2025at least $86,364,865at least 79,5803 of 42
Q4 2025at least $89,081,540at least 82,4005 of 45

By quarter, 2026 (posted so far)

Q1 2026at least $99,701,709at least 91,3054 of 45

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.